PMID- 27494666
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20180313
IS  - 1875-9777 (Electronic)
IS  - 1875-9777 (Linking)
VI  - 19
IP  - 2
DP  - 2016 Aug 4
TI  - ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity.
PG  - 141-142
LID - S1934-5909(16)30207-7 [pii]
LID - 10.1016/j.stem.2016.07.012 [doi]
AB  - Leukemic stem cells (LSCs) drive progression of chronic myeloid leukemia (CML) 
      and tyrosine kinase inhibitor resistance through poorly understood mechanisms. 
      Now in Cell Stem Cell, Zipeto et al. (2016) show targeting the RNA editing enzyme 
      ADAR1 restores expression of let-7 and efficiently kills LSCs, providing an 
      innovative therapeutic target in CML.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Zhang, Wen Cai
AU  - Zhang WC
AD  - Institute for RNA Medicine, Department of Pathology, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, 
      USA.
FAU - Slack, Frank J
AU  - Slack FJ
AD  - Institute for RNA Medicine, Department of Pathology, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, 
      USA. Electronic address: fslack@bidmc.harvard.edu.
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cell Stem Cell
JT  - Cell stem cell
JID - 101311472
RN  - 0 (MicroRNAs)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
CON - Cell Stem Cell. 2016 Aug 4;19(2):177-91. PMID: 27292188
MH  - Disease Progression
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MH  - *MicroRNAs
MH  - Neoplastic Stem Cells/*drug effects
MH  - Protein Kinase Inhibitors
EDAT- 2016/08/06 06:00
MHDA- 2017/08/09 06:00
CRDT- 2016/08/06 06:00
PHST- 2016/08/06 06:00 [entrez]
PHST- 2016/08/06 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
AID - S1934-5909(16)30207-7 [pii]
AID - 10.1016/j.stem.2016.07.012 [doi]
PST - ppublish
SO  - Cell Stem Cell. 2016 Aug 4;19(2):141-142. doi: 10.1016/j.stem.2016.07.012.